Type 1 diabetes: Prescription of GLP-1 receptor agonists and SGLT2 inhibitors

被引：0
|
作者：
Simon, Annika
机构：
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期
关键词：
D O I：
10.1055/a-2451-3561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Two relatively new classes of antidiabetic drugs - GLP-1 receptor agonists (GLP-1-RAs) and SGLT2 inhibitors (SGLT2-Is) - show positive effects on cardiovascular mortality and weight management in people with type 2 diabetes. Since there is also evidence that patients with type 1 diabetes could also benefit, Li et al. conducted a data analysis on current prescribing practices.
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [21] A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
    Consoli, Agostino
    Formoso, Gloria
    Baldassarre, Maria Pompea Antonia
    Febo, Fabrizio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (03) : 293 - 302
  • [22] GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
    Patel, Rushin
    Wadid, Mark
    Makwana, Bhargav
    Kumar, Ashish
    Khadke, Sumanth
    Bhatti, Ammar
    Banker, Ahan
    Husami, Zaid
    Labib, Sherif
    Venesy, David
    Fonarow, Gregg
    Kosiborod, Mikhail
    Al-Kindi, Sadeer
    Bhatt, Deepak L.
    Dani, Sourbha
    Nohria, Anju
    Butler, Javed
    Ganatra, Sarju
    JACC-HEART FAILURE, 2024, 12 (11) : 1814 - 1826
  • [23] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [24] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [25] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [26] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Suzanne V. Arnold
    Fengming Tang
    Andrew Cooper
    Hungta Chen
    Marilia B. Gomes
    Wolfgang Rathmann
    Iichiro Shimomura
    Jiten Vora
    Hirotaka Watada
    Kamlesh Khunti
    Mikhail Kosiborod
    BMC Endocrine Disorders, 22
  • [27] Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
    Edwards, Khary
    Li, Xilong
    Lingvay, Ildiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 920 - 930
  • [28] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [29] GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
    Neves, Joao Sergio
    Borges-Canha, Marta
    Vasques-Novoa, Francisco
    Green, Jennifer B.
    Leiter, Lawrence A.
    Granger, Christopher B.
    Carvalho, Davide
    Leite-Moreira, Adelino
    Hernandez, Adrian F.
    Del Prato, Stefano
    McMurray, John J. V.
    Md, Joao Pedro Ferreira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 517 - 525
  • [30] Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
    Olanrewaju, Olusegun A.
    Sheeba, Fnu
    Kumar, Avinash
    Ahmad, Saad
    Blank, Narendar
    Kumari, Reema
    Kumari, Komal
    Salame, Tamara
    Khalid, Ayesha
    Yousef, Nazdar
    Varrassi, Giustino
    Khatri, Mahima
    Kumar, Satish
    Mohamad, Tamam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
12345